DCB Taiwan Resource Center

Welcome to your Citeline resource center

Everything your team needs — training, intelligence, and dedicated support — in one place.

Your Solutions

Our people

Meet the team

Julie Guan (China)

Head of Strategic Accounts

View profile

Youmin Zhu (China)

Client Success Manager

View profile

Training & Help

We provide product training support via online sessions/pre-recorded materials, please click below to access relevant contents, or reach out to this email for any customized training request: pharmacs@citeline.com

 

Pre-recorded (教程视频)   Live Session – Clinical (公开培训) Live Session – Commercial (公开培训)

 


 

For access or technical issues, please contact your dedicated support team via ‘Meet the Team’, or contact Client Service team via below email:
若有任何登录问题,请切换至Meet the Team版面并联系对接服务团队,或可联系全球/亚太客服团队:

Global – clientservices@citeline.com (English only)

APAC – pharmacs@citeline.com (via English/Chinese)

Ask the analyst

Require Research Support?

Your status as a loyalty partner includes unlimited access to our highly acclaimed Ask-the-Analyst™ service. With a 24-hour response time, Ask-the-Analyst offers you authoritative information to help you make faster, smarter business decisions.

作为重点合作伙伴,贵司用户均可无限量使用Ask-the-Analyst™分析师咨询服务!分析师团队将会在24小时内回复(工作日)并为您提供信息收集或专业见解,最终助您做出更快、更明智的业务决策。

Our Ask-the-Analyst team of industry experts leverages the complete suite of pharma intelligence products and publicly available sources to bring you the answers you’re looking for, while your information and all questions received are strictly confidential.

由业界专家组成的分析师团队将结合内部数据与公开领域资源为您提供支持,您的个人资讯与提问内容均会被严格保密。

Latest Pharma Monthly Newsletter

Edition: August 2026

 

Download Report (English)

 

Download Report (Chinese)

 

EDITORIAL CONTENTS (incl. Podcasts, Webinars)

  • Webinar: The China
    Advantage: Rewriting Clinical Development (SEP 24, 10am EST | Register)
  • Webinar: Global Clinical Trial Disclosure: Are You
    Casting a Line or a Net? (SEP 29, 11am EST | Register)

 

DEALS & FINANCING (incl. M&As, Licensing, Financing)

  • M&A: Curium to Acquire Lantheus for up to $8B
  • M&A: Integer Holdings to be Taken Private Through KKR Buy-Out for $5.7B
  • M&A: Jazz to Acquire Actio Biosciences for up to $1.3B
  • Licensing: Genentech Enters $2.3B Licensing Agreement with Hanmi for Obesity Candidate ($190M
    upfront)
  • Licensing: Alphamab Oncology Licenses TROP2/HER3 Bispecific ADC to Pathos AI in Potential $2.2B
    Deal ($125M upfront)
  • Licensing: SK Biopharmaceuticals to In-License Epilepsy Drug Candidate ‘Opakalim’ from Biohaven
    totalling $795M ($400M upfront)
  • Financing: Braveheart Bio Nets $409M in Nasdaq IPO; Overallotment Fully Exercised
  • Financing: Vaderis Raises $152M in Series B Financing
  • Financing: Expedition Therapeutics Raises $115M in Oversubscribed Series B Round

 

KEY R&D EVENTS (incl. Top-line Readouts, Analyst Commentary, Approval/CRL)

  • Positive: Agenus | BOT+BAL Updated
    Phase 2 NEST publication demonstrates zero recurrences and deep pathologic responses in resectable colon
    cancer
  • Positive: AstraZeneca | Tagrisso + Orpathys delivers dual PFS and OS win in
    MET-driven post-Tagrisso NSCLC
  • Positive: Moderna | mRNA cancer therapy delivers first Phase III win, validating
    the intismeran platform and extending Merck’s melanoma franchise
  • Positive: Alumis | Alumis envudeucitinib’s long-term data supports a credible
    third TYK2 alternative, but not as category leader
  • Positive:Agenus | Off-the-Shelf iNKT Cell Therapy Shows Early Promise Where No
    Approved Treatment Exists
  • Negative: Tenax | TNX-103 misses Phase III LEVEL primary endpoint in PH-HFpEF
    but efficacy and biomarker signals support development in enriched population
  • Negative: Bausch + Lomb | Phase II miss at day 29 narrows lifitegrast +
    perfluorohexyloctane dual-action dry eye claim to speed of onset

 

RESEARCH REPORTS (incl. Forecast, Thought Leadership, KOL
Interview)

    • Report: The Use of AI in Pharmaceutical Commercialization: Insights from the Field (Link)
    • Report: Radiopharmaceuticals Landscape Snapshot (Link)
    • Report: Dealmaking Quarterly Statistics, Q2 2026
    • Report: Financing Quarterly Statistics, Q2 2026
    • Report: What Good LBE Forecasting Actually Looks Like
    • Report: Epi & Market Forecast – Breast Cancer HER2+ | Depression | Systemic Lupus
      Erythematosus
    • Report: KOL Interview – HER2-Positive Breast Cancer

 


Latest Editorial Podcasts

 

Listen Now – Global Insights

 

Listen Now – Chinese Contents